# Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

> **NCT04055753** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Doxil
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT04055753
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-08-12
- **Primary completion:** 2026-10-15
- **Final completion:** 2027-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055753, "Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04055753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*